Open AccessDoes severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series
Author(s) -
Tine Rosenberg,
Annette Dam Fialla,
Jens Kjeldsen,
Anette Drøhse Kjeldsen
Publication year - 2019
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.275
H-Index - 57
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhin18.289
Subject(s) - medicine , bevacizumab , population , randomized controlled trial , surgery , dermatology , intensive care medicine , chemotherapy , environmental health
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients.